Dr Andreas Goppelt
Chief Technology Officer (CTO)
As Chief Technology Officer (CTO), Dr Andreas Goppelt has been in charge of Research and Development at Ottobock since September 2017. Goppelt was previously managing director of Otto Bock Mobility Solutions GmbH, the company’s wheelchair business. He joined the Ottobock Group in 2015 as managing director of nstim NeuroBionics GmbH.
Goppelt was a consultant for biopharmaceuticals and medical technology between 2013 and 2015. From 2005 to 2013, he served as head of R&D for the BioSurgery and Regenerative Medicine business unit at Baxter. Goppelt began his career in business in 1997 as co-founder and chief scientific officer of biotech company Switch Biotech AG, which specialises in curing wound healing disorders and skin diseases.
A native of Erlangen, he studied chemistry at Ludwig Maximilian University (LMU) in Munich and earned his doctorate in biochemistry. After earning his doctorate, Goppelt worked as a postdoc at the LMU’s gene centre and the Max-Planck Institute for Biochemistry in Martinsried, Germany.